Nemaura Medical

Nemaura Medical, Inc. operates as a holding company. The firm engages in the provision of medical device research. It manufactures and commercializes glucose monitoring system, named sugarBEAT. The sugarBEAT consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals with the use of a mobile app. The company was founded by Dewan Fazlul Hoque Chowdhury on December 24, 2013 and is headquartered in New York, NY.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), today announced it has entered into a letter of intent with Healthimation, LLC (“Healthimation”) relating to a possible acquisition of the Healthimation business by Nemaura.

Nemaura Enters into Letter of Intent to Acquire Healthimation, LLC to Augment proBEAT™ Launch in the U.S.

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), today announced that it has commissioned the integration of data from third party wearable devices into its proBEAT™ app which is planned for launch in the USA later this year.

Nemaura Medical to Integrate Activity Data From Third Party Wearable Devices to Its proBEAT™ App

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced

Nemaura Medical Submits PMA Application for sugarBEAT® to U.S. FDA

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a business update and released financial results for the fiscal year ended March 31, 2020

Nemaura Medical Reports Results and Provides Business Update for the Fiscal Year Ended March 31, 2020

Nemaura Medical Interview to Air on Bloomberg International on the RedChip Money Report

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced

Nemaura Medical CEO to Participate in Investor Webinar and Q&A Session on July 7, 2020

There are a number of medical technology companies  that have gained momentum in an otherwise pessimistic market amid the Covid-19 pandemic.

Nemaura Medical: The Potential proBEAT Launch Adds Some Steam

The company's continuous glucose monitor is a potential breakthrough in the diabetes diagnostics space, and also the reason why its stock has gained momentum

Nemaura Medical: A Diabetes-Oriented Med-Tech Play

Loughborough, England, Feb.  11, 2020  (GLOBE NEWSWIRE) --   Nemaura Medical, Inc.  (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a business update and financial results for the third quarter ended December 31, 2019.

Nemaura Medical Reports Results and Provides Business Update for the Third Quarter Ended December 31, 2019

Loughborough, England, Dec.  20, 2019  (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a 2019 year-end corporate update.

Nemaura Provides 2019 Year-End Corporate Update

Nemaura and Changing Health to provide innovative digital education and personalized coaching to enhance outcomes for people with diabetes and prediabetes Nemaura and Changing Health to provide innovative digital education and personalized coaching to enhance outcomes for people with diabetes and prediabetes

Nemaura Medical and Changing Health announce Partnership to provide award-winning Diabetes Behavioral Change services

BEAT® Diabetes utilizes SugarBEAT® CGM data to provide holistic coaching services via user-friendly app to enhance outcomes for diabetic and pre-diabetic patients  BEAT® Diabetes utilizes SugarBEAT® CGM data to provide holistic coaching services via user-friendly app to enhance outcomes for diabetic and pre-diabetic patients

Nemaura Medical announces expansion of SugarBEAT® offering  with BEAT® Diabetes digital subscription services

Loughborough, England, Dec.  04, 2019  (GLOBE NEWSWIRE) --  Nemaura Medical, Inc.  (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced plans to conduct reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share on a one 1 for 10 basis.  The reverse split is expected to take effect at the market open on December 5, 2019. The new CUSIP number will be 640442208.

Nemaura Medical Announces 1 for 10 Reverse Split  Intended to Attract a Wider Universe of Institutional Investors

Loughborough, England, Nov.  11, 2019  (GLOBE NEWSWIRE) --  –  Nemaura Medical, Inc.  (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the second quarter ended September 30, 2019.

Nemaura Medical Reports Results and Provides Business Update for the Second Quarter Ended September 30, 2019

Loughborough, England , Sept.  12, 2019  (GLOBE NEWSWIRE) -- Loughborough, England – September 12, 2019 –    Nemaura Medical, Inc.    (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that Dr. Faz Chowdhury, Chief Executive Officer, Dr. Fred Schaebsdau, VP Strategic Alliances, and Dr Iain Cranson, a diabetes specialist based in the UK, will be presenting at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) on Thursday, September 19, 2019 at 18:45 - 20:15 Central European Time at the Fira Barcelona Gran Via (Maimonides Hall) in Barcelona, Spain.  The evening symposia will focus on the historic development of SugarBEAT®, its application to all categories of diabetics and diabetes management, clinical data and recent user experiences.  The presentation is titled: “SugarBEAT® Non-Invasive CGM User Study Results: Diagnostic and Monitoring Applications Across Different Patient Types and Clinical Settings.”

Nemaura Medical to Hold a Symposia at EASD in Barcelona on Thursday September 19, 2019

News for Nemaura Medical Stock (NMRD)